These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 37458671)

  • 1. Oxidative stress and inflammation in COVID-19: potential application OF GLP-1 receptor agonists.
    Abudalo RA; Alqudah AM; Roarty C; Athamneh RY; Grieve DJ
    Eur Rev Med Pharmacol Sci; 2023 Jul; 27(13):6459-6471. PubMed ID: 37458671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential role of tirzepatide towards Covid-19 infection in diabetic patients: a perspective approach.
    Batiha GE; Al-Kuraishy HM; Al-Gareeb AI; Ashour NA; Negm WA
    Inflammopharmacology; 2023 Aug; 31(4):1683-1693. PubMed ID: 37208555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
    Nauck MA; Meier JJ; Cavender MA; Abd El Aziz M; Drucker DJ
    Circulation; 2017 Aug; 136(9):849-870. PubMed ID: 28847797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GLP-1 Receptor Agonists in Type 2 Diabetes Mellitus.
    Dahiya L; Kaur R; Kumar R; Kumar M; Palta K
    Curr Diabetes Rev; 2020; 16(4):279-292. PubMed ID: 31057118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glucagon-like peptide-1 receptor agonists in the era of COVID-19: Friend or foe?
    Belančić A; Kresović A; Troskot Dijan M
    Clin Obes; 2021 Apr; 11(2):e12439. PubMed ID: 33423388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of GLP-1 receptor agonists during COVID-19 pandemia: a hypothetical molecular mechanism.
    Banerjee Y; Pantea Stoian A; Silva-Nunes J; Sonmez A; Rizvi AA; Janez A; Rizzo M
    Expert Opin Drug Saf; 2021 Nov; 20(11):1309-1315. PubMed ID: 34424130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human epicardial adipose tissue expresses glucose-dependent insulinotropic polypeptide, glucagon, and glucagon-like peptide-1 receptors as potential targets of pleiotropic therapies.
    Malavazos AE; Iacobellis G; Dozio E; Basilico S; Di Vincenzo A; Dubini C; Menicanti L; Vianello E; Meregalli C; Ruocco C; Ragni M; Secchi F; Spagnolo P; Castelvecchio S; Morricone L; Buscemi S; Giordano A; Goldberger JJ; Carruba M; Cinti S; Corsi Romanelli MM; Nisoli E
    Eur J Prev Cardiol; 2023 Jun; 30(8):680-693. PubMed ID: 36799940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glucagon-like peptide-1 receptor agonists improve biomarkers of inflammation and oxidative stress: A systematic review and meta-analysis of randomised controlled trials.
    Bray JJH; Foster-Davies H; Salem A; Hoole AL; Obaid DR; Halcox JPJ; Stephens JW
    Diabetes Obes Metab; 2021 Aug; 23(8):1806-1822. PubMed ID: 33830637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular benefits of GLP-1 agonists in type 2 diabetes: a comparative review.
    Boyle JG; Livingstone R; Petrie JR
    Clin Sci (Lond); 2018 Aug; 132(15):1699-1709. PubMed ID: 30115742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The postprandial actions of GLP-1 receptor agonists: The missing link for cardiovascular and kidney protection in type 2 diabetes.
    Thomas MC; Coughlan MT; Cooper ME
    Cell Metab; 2023 Feb; 35(2):253-273. PubMed ID: 36754019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of GLP-1 Analogs in the Management of Diabetes and its Secondary Complication.
    Sivakumar PM; Premkumar B; Prabhawathi V; Prabhakar PK
    Mini Rev Med Chem; 2021; 21(20):3166-3182. PubMed ID: 33888049
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular benefits of SGLT2 inhibitors and GLP-1 receptor agonists through effects on mitochondrial function and oxidative stress.
    Luna-Marco C; Iannantuoni F; Hermo-Argibay A; Devos D; Salazar JD; Víctor VM; Rovira-Llopis S
    Free Radic Biol Med; 2024 Mar; 213():19-35. PubMed ID: 38220031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control?
    Grieve DJ; Cassidy RS; Green BD
    Br J Pharmacol; 2009 Aug; 157(8):1340-51. PubMed ID: 19681866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Review of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes mellitus in patients with chronic kidney disease and their renal effects.
    Sloan LA
    J Diabetes; 2019 Dec; 11(12):938-948. PubMed ID: 31318152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diabetes, Drug Treatment, and Mortality in COVID-19: A Multinational Retrospective Cohort Study.
    Nyland JE; Raja-Khan NT; Bettermann K; Haouzi PA; Leslie DL; Kraschnewski JL; Parent LJ; Grigson PS
    Diabetes; 2021 Dec; 70(12):2903-2916. PubMed ID: 34580086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incretins and cardiovascular disease: to the heart of type 2 diabetes?
    Solini A; Tricò D; Del Prato S
    Diabetologia; 2023 Oct; 66(10):1820-1831. PubMed ID: 37542009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors for cardiovascular and renal protection: A treatment approach far beyond their glucose-lowering effect.
    Gómez-Huelgas R; Sanz-Cánovas J; Cobos-Palacios L; López-Sampalo A; Pérez-Belmonte LM
    Eur J Intern Med; 2022 Feb; 96():26-33. PubMed ID: 34799233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes and Cardiovascular Disease: A Review.
    Honigberg MC; Chang LS; McGuire DK; Plutzky J; Aroda VR; Vaduganathan M
    JAMA Cardiol; 2020 Oct; 5(10):1182-1190. PubMed ID: 32584928
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparable COVID-19 outcomes with current use of GLP-1 receptor agonists, DPP-4 inhibitors or SGLT-2 inhibitors among patients with diabetes who tested positive for SARS-CoV-2.
    Israelsen SB; Pottegård A; Sandholdt H; Madsbad S; Thomsen RW; Benfield T
    Diabetes Obes Metab; 2021 Jun; 23(6):1397-1401. PubMed ID: 33502076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucagon-like peptide-1 receptor agonists and heart failure in type 2 diabetes: systematic review and meta-analysis of randomized and observational studies.
    Li L; Li S; Liu J; Deng K; Busse JW; Vandvik PO; Wong E; Sohani ZN; Bala MM; Rios LP; Malaga G; Ebrahim S; Shen J; Zhang L; Zhao P; Chen Q; Wang Y; Guyatt GH; Sun X
    BMC Cardiovasc Disord; 2016 May; 16():91. PubMed ID: 27169565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.